$38.59
0.68%
Nasdaq, Sep 02, 06:47 pm CET
ISIN
US7665596034
Symbol
RIGL

Rigel Pharmaceuticals, Inc. Stock price

$38.85
+18.95 95.23% 1M
+15.79 68.47% 6M
+22.03 130.98% YTD
+25.30 186.72% 1Y
+24.75 175.53% 3Y
+13.95 56.02% 5Y
+8.85 29.50% 10Y
-151.75 79.62% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.46 1.17%
ISIN
US7665596034
Symbol
RIGL
Industry

Key metrics

Basic
Market capitalization
$696.9m
Enterprise Value
$648.3m
Net debt
positive
Cash
$108.4m
Shares outstanding
17.9m
Valuation (TTM | estimate)
P/E
7.2 | 6.9
P/S
2.6 | 2.4
EV/Sales
2.4 | 2.3
EV/FCF
9.8
P/B
8.5
Financial Health
Equity Ratio
2.0%
Return on Equity
531.8%
ROCE
87.1%
ROIC
186.9%
Debt/Equity
0.7
Financials (TTM | estimate)
Revenue
$267.9m | $286.7m
EBITDA
$107.0m | $56.2m
EBIT
$104.6m | $76.1m
Net Income
$97.8m | $101.7m
Free Cash Flow
$65.8m
Growth (TTM | estimate)
Revenue
105.6% | 59.9%
EBITDA
1,542.2% | 112.6%
EBIT
1,259.1% | 214.4%
Net Income
787.4% | 481.5%
Free Cash Flow
619.6%
Margin (TTM | estimate)
Gross
91.5%
EBITDA
39.9% | 19.6%
EBIT
39.0%
Net
36.5% | 35.5%
Free Cash Flow
24.6%
More
EPS
$5.4
FCF per Share
$3.7
Short interest
11.4%
Employees
163
Rev per Employee
$1.1m
Show more

Is Rigel Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Rigel Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

7x Buy
58%
5x Hold
42%

Analyst Opinions

12 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

Buy
58%
Hold
42%

Financial data from Rigel Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
268 268
106% 106%
100%
- Direct Costs 23 23
130% 130%
8%
245 245
104% 104%
92%
- Selling and Administrative Expenses 114 114
5% 5%
42%
- Research and Development Expense 27 27
28% 28%
10%
107 107
1,542% 1,542%
40%
- Depreciation and Amortization 2.43 2.43
52% 52%
1%
EBIT (Operating Income) EBIT 105 105
1,259% 1,259%
39%
Net Profit 98 98
787% 787%
37%

In millions USD.

Don't miss a Thing! We will send you all news about Rigel Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rigel Pharmaceuticals, Inc. Stock News

Neutral
PRNewsWire
7 days ago
SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in Se...
Positive
Seeking Alpha
20 days ago
Rigel's Q2 results were outstanding, with revenue nearly doubling and net income surging, driven by strong commercial momentum for TAVALISSE, GAVRETO, and REZLIDHIA. Management raised 2025 guidance, expecting positive net income and robust sales growth, signaling Rigel's transition to a self-sustaining, growth-focused biotech. Pipeline progress, especially with R289 and REZLIDHIA label expansio...
Positive
The Motley Fool
27 days ago
Rigel (RIGL) Q2 Revenue Jumps 176%
More Rigel Pharmaceuticals, Inc. News

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Head office United States
CEO Raul Rodriguez
Employees 163
Founded 1996
Website www.rigel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today